Brief: Aligos Therapeutics Reports Fourth Quarter And Full Year 2022 Financial Results
09/03/2023 21:24
March 9 (Reuters) - Aligos Therapeutics Inc ALGS.O :
* ALIGOS THERAPEUTICS REPORTS RECENT BUSINESS PROGRESS AND
FOURTH
QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
* QTRLY LOSS PER SHARE $0.51
* WE CONTINUE TO BELIEVE OUR CASH BALANCE PROVIDES
SUFFICIENT CASH
TO FUND PLANNED OPERATIONS THROUGH END OF 2024
* Q4 EARNINGS PER SHARE VIEW $-0.47 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX7QXvXw
Further company coverage: ALGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue